Altimmune shares are trading higher after the company presented data from its Phase 2 MRI-based body composition sub-study of pemvidutide in subjects overweight or with obesity.
Portfolio Pulse from Benzinga Newsdesk
Altimmune shares rose following the presentation of positive data from its Phase 2 study on pemvidutide, targeting overweight and obese individuals.
September 10, 2024 | 5:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Altimmune's stock price increased after the company presented promising data from its Phase 2 study of pemvidutide, which focuses on treating overweight and obesity.
The positive data from the Phase 2 study of pemvidutide is likely to boost investor confidence in Altimmune's product pipeline, leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100